Key Points
-
Interested in NRx Pharmaceuticals, Inc.? Here are five stocks we like better.
-
NRx Pharmaceuticals received FDA approvalfor its preservative-free ketamine injection, its first approved product and a major step toward becoming a commercial pharmaceutical company.
-
The company is targeting the persistent U.S. ketamine shortage with a domestically manufactured product and has ordered 5 million vialsfor launch inventory. Initial shipments will focus on hospitals, wholesalers, group purchasing organizations and clinics.
-
NRx sees a U.S. ketamine market that could approach $400 million by 2027and plans to expand into additional vial sizes, shortage-affected sterile injectables and its broader CNS drug-development pipeline.
-
5 Biotech stocks tapping into unmet mental health treatment needs
NRx Pharmaceuticals (NASDAQ:NRXP) said the U.S. Food and Drug Administration approved its abbreviated new drug application for preservative-free ketamine injection, marking the company's first approved product and its transition from a development-stage company to a commercial pharmaceutical company.
The FDA approval arrived ahead of the company's Nov. 10 goal date, according to Founder, Chairman and Chief Executive Officer Jonathan Javitt. Javitt said the ANDA was approved in less than 14 months after submission, compared with an average ANDA approval timeline of 35.6 months cited from FDA data.
→ Apple's Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
-
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
NRx did not provide revenue or margin guidance during the call. However, Javitt said the U.S. ketamine market, at a current price of $5 per vial, could approach $400 million in 2027. He also said ketamine demand grew 17% in 2025, driven in part by use in pain-control settings as hospitals seek alternatives to opioids.
U.S.-Made, Preservative-Free Product
The approved product is manufactured in West Columbia, South Carolina, through NRx's partner Nephron Pharmaceuticals. It uses blow-fill-seal technology and a Luer-lock tip rather than conventional glass vials, a format Javitt said can reduce packaging costs, simplify medication preparation and eliminate needle-stick risks associated with withdrawing medication from glass containers.
→ Off-Price, High-Yield: Why Ross Stores Is Defying the Retail Slump
Javitt said the company's vial is classified by the FDA as a drug-device combination, and that the device component received review from both the FDA's Office of Generic Drugs and Center for Devices and Radiological Health.
Existing ketamine injection products in the U.S. contain preservatives, principally benzethonium chloride, or BZT, according to Javitt. He said NRx's preservative-free formulation was designed to address concerns over exposure to the preservative, particularly among patients receiving longer critical-care or pain-management infusions and certain vulnerable populations.
→ Coca-Cola Stock Is Everything AI Isn't—And That's Its Biggest Strength
NRx has filed a Citizen Petition asking the FDA to remove BZT from ketamine products. Javitt said the company has a patent application in prosecution covering the preservative-free formulation, as well as intellectual property related to the drug-device packaging combination. He declined to comment on the ultimate strength or enforceability of the patent portfolio.
Supply Shortage Drives Commercial Focus
Javitt said ketamine injection has appeared on the national drug shortage list since February 2018. He cited the American Society of Health-System Pharmacists in saying that all six ketamine manufacturers had at least one product presentation that was back-ordered, intermittent or on allocation as of the current month.
The company believes the shortage reflects the economics of conventional sterile injectable manufacturing, which generally relies on pharmaceutical-grade glass bottles and overseas production. Javitt said NRx's manufacturing technology can package roughly 1 million doses in the time a conventional glass bottling line can package 10,000 to 50,000 doses.
"The first priority for hospital buying groups is not about preservative-free," Javitt said during the question-and-answer session. "The first priority is assured supply."
NRx said it has ordered 5 million vials as launch inventory, with Nephron building that stock through December. The company expects to manufacture future inventory in million-vial batches. First shipments are expected once sufficient stock is available to support committed hospital customers.
Launch Plan Targets Hospitals, GPOs and Clinics
The company plans to pursue three commercial channels:
-
Hospitals:NRx said approximately 17% of U.S. hospitals, or about 1,200 customers, purchase roughly 80% of hospital ketamine. The company's sales team will initially target those accounts with supply agreements and account plans.
-
Wholesalers and group purchasing organizations:NRx said it has access through Nephron's existing contracts with wholesalers and GPOs. Javitt identified McKesson, Cardinal and Cencora as distributors representing about 90% of U.S. ketamine distribution, while Vizient, Premier and HealthTrust collectively cover about 80% of hospital beds.
-
Clinics:The company has partnered with Osmind, a medical-record vendor focused on interventional psychiatry, to offer an ordering platform for affiliated clinics. NRx said it will not promote ketamine for off-label uses.
Javitt said the company expects its first three months after shipment to focus on converting its top tier of hospital customers. Months four through six are expected to expand outreach to additional hospitals, health systems and GPOs, while months seven through 12 will focus on growing share within existing accounts.
Additional Products and CNS Programs
NRx plans to introduce additional ketamine vial sizes and strengths beginning in 2027 and expects to receive a new manufacturing line from Germany in the first quarter of 2027. Javitt said the company also intends to evaluate other sterile injectable drugs with supply shortages, whether or not they are focused on central nervous system conditions.
The company continues to develop its CNS pipeline, including NRX-101, an oral antidepressant being evaluated in a DARPA-funded Phase 3 trial in combination with transcranial magnetic stimulation. Javitt said NRx plans to discuss newly obtained data comparing intravenous ketamine with Spravato during its next quarterly earnings call.
"We want people to recognize that they're seeing an emerging U.S. pharmaceutical company that's committed to U.S. manufacture of innovative products," Javitt said.
About NRx Pharmaceuticals (NASDAQ:NRXP)
NRx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly severe depression and suicidal ideation. The company's research programs are designed to address conditions in which existing therapies may have limited effectiveness or delayed onset.
NRx's lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
The article " NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection " was originally published by MarketBeat.
